-
Chasing Metastatic Cancer Cells
Understanding cancer cell behavior is a fundamental step toward advancing precision medicine. Winship’s Adam Marcus, PhD, shows how his lab is isolating and studying the behavior “leader” cells that may be the key to cancer metastasis.
Video won first place in the Association of American Medical Colleges' 2015 Basic Research Video Contest.
Visit the Marcus Lab on the web at http://www.marcuslab.com.
To learn more about Winship Cancer Institute of Emory University, visit https://winshipcancer.emory.edu.
published: 28 Sep 2015
-
Understanding metastatic breast cancer
To learn more visit http://www.YouAndBreastCancer.com
This animation explains what metastatic breast cancer is, the symptoms to watch for, and the wide variety of treatment options available. If you have metastatic breast cancer you will likely need to remain on treatment, unless you choose to stop it. Being diagnosed with metastatic breast cancer can be overwhelming. But many people continue to live long, productive lives with breast cancer in this stage due to advances in treatment.
published: 08 Jun 2018
-
What does it mean if a patient has "metastatic lung cancer"?
Learn more about lung cancer at http://www.YouAndLungCancer.com
The words “metastatic lung cancer” can mean a lot of different things and it is an important topic to discuss with your doctor as it may relate to your situation. In the past patients with “metastatic lung cancer” were considered untreatable when it came to surgery. Today we have a more hopeful situation. For example, there is a new term that sounds very complex and it is called “Oligometastatic lung cancer”. In these patients surgery can be an option to consider.
published: 06 Nov 2017
-
Cancer Basics – What is metastatic cancer?
When you’re diagnosed with metastatic cancer, you may be confused and not know what to do next. This video explains metastatic cancer and the goals of treatment. It also shows how the Canadian Cancer Society can help you find services in your community to improve your quality of life and how to connect with others across Canada.
The Cancer Basics video series is proudly sponsored by BMO.
published: 30 Jan 2023
-
What is Metastatic Liver Cancer?
Co-Director of Roswell Park's Liver and Pancreas Tumor Center, Renuka Iyer, MD, discusses Metastatic Liver Cancer.
published: 09 Sep 2019
-
Metastatic Bone Cancer: Bone Pain When Breast & Prostate Cancer Spreads
When cancer cells travel from the bone to another place on the body, it’s called metastatic cancer to the bone. Gregory Domson, MD, explains that this happens more with breast or prostate cancer. Patients will notice bone pain or a lump around a bone, and it’s a symptom of something that’s wrong.
For more information, https://uvahealth.com/services/bone-cancer
In adults, the most common form of bone cancer is when cancer from another organ has traveled to the bone. It has metastasized to the bone. That’s what you see most commonly in the adult population.
In women, it’s commonly breast cancer. In men, it’s commonly prostate cancer. The most common primary presenting symptom is pain. So, if you have bone pain, that’s going to be a clear indicator that something is going on. In some case...
published: 09 May 2019
-
Episode 102:Advancing Nursing Practice in Prostate Cancer Management:Clinical Evidence,Novel Agents
Join UroNurse for a shared viewing of a webcast recorded at the Conversations in Primary Care: 2023 - Virtual Broadcast Live on May 20, 2023 and is being used with the permission of the presenters.
Although effective treatments are available, many patients with prostate cancer eventually experience disease progression. As novel hormonal therapies and other emerging agents are introduced earlier in the disease course, treatment decision-making is becoming increasingly personalized, requiring consideration of novel risk factors, molecular imaging, and patient preferences as well as established clinical and pathological factors. Clinicians must be aware of the recent evidence regarding new therapies and combinations and be able to support and educate patients as they weigh the benefits and ...
published: 14 Jul 2024
-
Introduction to Cancer Biology (Part 3): Tissue Invasion and Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 200...
published: 27 Oct 2012
-
Cancer - Metastasis
https://www.facebook.com/ArmandoHasudungan
Support me:
http://www.patreon.com/armando
Instagram:
http://instagram.com/armandohasudungan
Twitter:
https://twitter.com/Armando71021105
published: 02 Dec 2013
-
Understanding Metastatic Colon Cancer
published: 06 Feb 2020
4:00
Chasing Metastatic Cancer Cells
Understanding cancer cell behavior is a fundamental step toward advancing precision medicine. Winship’s Adam Marcus, PhD, shows how his lab is isolating and st...
Understanding cancer cell behavior is a fundamental step toward advancing precision medicine. Winship’s Adam Marcus, PhD, shows how his lab is isolating and studying the behavior “leader” cells that may be the key to cancer metastasis.
Video won first place in the Association of American Medical Colleges' 2015 Basic Research Video Contest.
Visit the Marcus Lab on the web at http://www.marcuslab.com.
To learn more about Winship Cancer Institute of Emory University, visit https://winshipcancer.emory.edu.
https://wn.com/Chasing_Metastatic_Cancer_Cells
Understanding cancer cell behavior is a fundamental step toward advancing precision medicine. Winship’s Adam Marcus, PhD, shows how his lab is isolating and studying the behavior “leader” cells that may be the key to cancer metastasis.
Video won first place in the Association of American Medical Colleges' 2015 Basic Research Video Contest.
Visit the Marcus Lab on the web at http://www.marcuslab.com.
To learn more about Winship Cancer Institute of Emory University, visit https://winshipcancer.emory.edu.
- published: 28 Sep 2015
- views: 26261
5:53
Understanding metastatic breast cancer
To learn more visit http://www.YouAndBreastCancer.com
This animation explains what metastatic breast cancer is, the symptoms to watch for, and the wide variety ...
To learn more visit http://www.YouAndBreastCancer.com
This animation explains what metastatic breast cancer is, the symptoms to watch for, and the wide variety of treatment options available. If you have metastatic breast cancer you will likely need to remain on treatment, unless you choose to stop it. Being diagnosed with metastatic breast cancer can be overwhelming. But many people continue to live long, productive lives with breast cancer in this stage due to advances in treatment.
https://wn.com/Understanding_Metastatic_Breast_Cancer
To learn more visit http://www.YouAndBreastCancer.com
This animation explains what metastatic breast cancer is, the symptoms to watch for, and the wide variety of treatment options available. If you have metastatic breast cancer you will likely need to remain on treatment, unless you choose to stop it. Being diagnosed with metastatic breast cancer can be overwhelming. But many people continue to live long, productive lives with breast cancer in this stage due to advances in treatment.
- published: 08 Jun 2018
- views: 304632
2:02
What does it mean if a patient has "metastatic lung cancer"?
Learn more about lung cancer at http://www.YouAndLungCancer.com
The words “metastatic lung cancer” can mean a lot of different things and it is an important top...
Learn more about lung cancer at http://www.YouAndLungCancer.com
The words “metastatic lung cancer” can mean a lot of different things and it is an important topic to discuss with your doctor as it may relate to your situation. In the past patients with “metastatic lung cancer” were considered untreatable when it came to surgery. Today we have a more hopeful situation. For example, there is a new term that sounds very complex and it is called “Oligometastatic lung cancer”. In these patients surgery can be an option to consider.
https://wn.com/What_Does_It_Mean_If_A_Patient_Has_Metastatic_Lung_Cancer
Learn more about lung cancer at http://www.YouAndLungCancer.com
The words “metastatic lung cancer” can mean a lot of different things and it is an important topic to discuss with your doctor as it may relate to your situation. In the past patients with “metastatic lung cancer” were considered untreatable when it came to surgery. Today we have a more hopeful situation. For example, there is a new term that sounds very complex and it is called “Oligometastatic lung cancer”. In these patients surgery can be an option to consider.
- published: 06 Nov 2017
- views: 20463
2:38
Cancer Basics – What is metastatic cancer?
When you’re diagnosed with metastatic cancer, you may be confused and not know what to do next. This video explains metastatic cancer and the goals of treatment...
When you’re diagnosed with metastatic cancer, you may be confused and not know what to do next. This video explains metastatic cancer and the goals of treatment. It also shows how the Canadian Cancer Society can help you find services in your community to improve your quality of life and how to connect with others across Canada.
The Cancer Basics video series is proudly sponsored by BMO.
https://wn.com/Cancer_Basics_–_What_Is_Metastatic_Cancer
When you’re diagnosed with metastatic cancer, you may be confused and not know what to do next. This video explains metastatic cancer and the goals of treatment. It also shows how the Canadian Cancer Society can help you find services in your community to improve your quality of life and how to connect with others across Canada.
The Cancer Basics video series is proudly sponsored by BMO.
- published: 30 Jan 2023
- views: 6912
1:54
What is Metastatic Liver Cancer?
Co-Director of Roswell Park's Liver and Pancreas Tumor Center, Renuka Iyer, MD, discusses Metastatic Liver Cancer.
Co-Director of Roswell Park's Liver and Pancreas Tumor Center, Renuka Iyer, MD, discusses Metastatic Liver Cancer.
https://wn.com/What_Is_Metastatic_Liver_Cancer
Co-Director of Roswell Park's Liver and Pancreas Tumor Center, Renuka Iyer, MD, discusses Metastatic Liver Cancer.
- published: 09 Sep 2019
- views: 77652
1:36
Metastatic Bone Cancer: Bone Pain When Breast & Prostate Cancer Spreads
When cancer cells travel from the bone to another place on the body, it’s called metastatic cancer to the bone. Gregory Domson, MD, explains that this happens m...
When cancer cells travel from the bone to another place on the body, it’s called metastatic cancer to the bone. Gregory Domson, MD, explains that this happens more with breast or prostate cancer. Patients will notice bone pain or a lump around a bone, and it’s a symptom of something that’s wrong.
For more information, https://uvahealth.com/services/bone-cancer
In adults, the most common form of bone cancer is when cancer from another organ has traveled to the bone. It has metastasized to the bone. That’s what you see most commonly in the adult population.
In women, it’s commonly breast cancer. In men, it’s commonly prostate cancer. The most common primary presenting symptom is pain. So, if you have bone pain, that’s going to be a clear indicator that something is going on. In some cases, you may have a painless mass, so you’ll feel a lump or a bump around a bone, and that’s an indicator that something is going on as well.
There are multiple forms of treatment. Surgically, what I do is sometimes removing the tumor, sometimes stabilizing the bone and preventing fracture. Also, there are also adjuvant treatments, like radiation treatment to the area, and medical treatment, like chemotherapy.
The biggest thing that UVA offers in treating patients with bone cancer is a multimodal approach. It’s a team approach. There’s more than one way to address these things and requires different specialists who are really good at what they do.
My job is kind of the nuts and bolts, where we want to keep the bones healthy and strong and prevent fractures, and minimize patients’ pain, keep them up and moving around when they have metastatic bone cancer. However, UVA also offers a variety of other services to treat these patients, which include radiation oncology, hematology-oncology, and a team approach.
https://wn.com/Metastatic_Bone_Cancer_Bone_Pain_When_Breast_Prostate_Cancer_Spreads
When cancer cells travel from the bone to another place on the body, it’s called metastatic cancer to the bone. Gregory Domson, MD, explains that this happens more with breast or prostate cancer. Patients will notice bone pain or a lump around a bone, and it’s a symptom of something that’s wrong.
For more information, https://uvahealth.com/services/bone-cancer
In adults, the most common form of bone cancer is when cancer from another organ has traveled to the bone. It has metastasized to the bone. That’s what you see most commonly in the adult population.
In women, it’s commonly breast cancer. In men, it’s commonly prostate cancer. The most common primary presenting symptom is pain. So, if you have bone pain, that’s going to be a clear indicator that something is going on. In some cases, you may have a painless mass, so you’ll feel a lump or a bump around a bone, and that’s an indicator that something is going on as well.
There are multiple forms of treatment. Surgically, what I do is sometimes removing the tumor, sometimes stabilizing the bone and preventing fracture. Also, there are also adjuvant treatments, like radiation treatment to the area, and medical treatment, like chemotherapy.
The biggest thing that UVA offers in treating patients with bone cancer is a multimodal approach. It’s a team approach. There’s more than one way to address these things and requires different specialists who are really good at what they do.
My job is kind of the nuts and bolts, where we want to keep the bones healthy and strong and prevent fractures, and minimize patients’ pain, keep them up and moving around when they have metastatic bone cancer. However, UVA also offers a variety of other services to treat these patients, which include radiation oncology, hematology-oncology, and a team approach.
- published: 09 May 2019
- views: 86458
49:02
Episode 102:Advancing Nursing Practice in Prostate Cancer Management:Clinical Evidence,Novel Agents
Join UroNurse for a shared viewing of a webcast recorded at the Conversations in Primary Care: 2023 - Virtual Broadcast Live on May 20, 2023 and is being used w...
Join UroNurse for a shared viewing of a webcast recorded at the Conversations in Primary Care: 2023 - Virtual Broadcast Live on May 20, 2023 and is being used with the permission of the presenters.
Although effective treatments are available, many patients with prostate cancer eventually experience disease progression. As novel hormonal therapies and other emerging agents are introduced earlier in the disease course, treatment decision-making is becoming increasingly personalized, requiring consideration of novel risk factors, molecular imaging, and patient preferences as well as established clinical and pathological factors. Clinicians must be aware of the recent evidence regarding new therapies and combinations and be able to support and educate patients as they weigh the benefits and risks of systemic therapy.
This enduring activity is designed to meet the educational needs of urology nurses as well as advanced practice urology nurses, nurse practitioners, and oncology nurses involved in the treatment of patients with advanced prostate cancer.
This activity is supported by unrestricted grants from Astellas and Pfizer Inc., AstraZeneca, Bayer, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Lantheus, Merck Sharp & Dohme LLC., and Novartis.
At the completion of viewing this you will be able to submit for free 1.00 / ANCC Contact Hour
*The information provided on the site is for educational purposes only, and does not substitute for professional medical advice. Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.
#ProstateCancer #NursingPractice #ClinicalEvidence #NovelTherapies #PatientCare #OncologyNursing #HealthcareInnovation
https://wn.com/Episode_102_Advancing_Nursing_Practice_In_Prostate_Cancer_Management_Clinical_Evidence,Novel_Agents
Join UroNurse for a shared viewing of a webcast recorded at the Conversations in Primary Care: 2023 - Virtual Broadcast Live on May 20, 2023 and is being used with the permission of the presenters.
Although effective treatments are available, many patients with prostate cancer eventually experience disease progression. As novel hormonal therapies and other emerging agents are introduced earlier in the disease course, treatment decision-making is becoming increasingly personalized, requiring consideration of novel risk factors, molecular imaging, and patient preferences as well as established clinical and pathological factors. Clinicians must be aware of the recent evidence regarding new therapies and combinations and be able to support and educate patients as they weigh the benefits and risks of systemic therapy.
This enduring activity is designed to meet the educational needs of urology nurses as well as advanced practice urology nurses, nurse practitioners, and oncology nurses involved in the treatment of patients with advanced prostate cancer.
This activity is supported by unrestricted grants from Astellas and Pfizer Inc., AstraZeneca, Bayer, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Lantheus, Merck Sharp & Dohme LLC., and Novartis.
At the completion of viewing this you will be able to submit for free 1.00 / ANCC Contact Hour
*The information provided on the site is for educational purposes only, and does not substitute for professional medical advice. Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.
#ProstateCancer #NursingPractice #ClinicalEvidence #NovelTherapies #PatientCare #OncologyNursing #HealthcareInnovation
- published: 14 Jul 2024
- views: 91
3:10
Introduction to Cancer Biology (Part 3): Tissue Invasion and Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation p...
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun;36(9):1171-9.
4. Potapova O, Fakhrai H, Mercola D. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer. 1996 May 29;66(5):669-77.
5. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003 Jan 17;278(3):1824-30.
6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178-82.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct;6(10):1251-9.
8. Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer. 2001 Oct 15;94(2):185-91.
9. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003; 35(5):327-36.
10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10;23(23):5386-403.
11. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005 Sep 20;23(27):6771-90.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13;103(2):253-62.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2(4):277-88.
15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec;1010:1-8.
16. Veiby OP, Read MA. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin Cancer Res. 2004 May 15;10(10):3333-41.
17. Foo P. Metastasis: The journey of mobile cancer cells. Harvard Science Review. Spring 2002;30-2.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23(5):1011-27.
19. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1007-21.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.
21. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
https://wn.com/Introduction_To_Cancer_Biology_(Part_3)_Tissue_Invasion_And_Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun;36(9):1171-9.
4. Potapova O, Fakhrai H, Mercola D. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer. 1996 May 29;66(5):669-77.
5. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003 Jan 17;278(3):1824-30.
6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178-82.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct;6(10):1251-9.
8. Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer. 2001 Oct 15;94(2):185-91.
9. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003; 35(5):327-36.
10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10;23(23):5386-403.
11. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005 Sep 20;23(27):6771-90.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13;103(2):253-62.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2(4):277-88.
15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec;1010:1-8.
16. Veiby OP, Read MA. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin Cancer Res. 2004 May 15;10(10):3333-41.
17. Foo P. Metastasis: The journey of mobile cancer cells. Harvard Science Review. Spring 2002;30-2.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23(5):1011-27.
19. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1007-21.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.
21. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
- published: 27 Oct 2012
- views: 457215
9:02
Cancer - Metastasis
https://www.facebook.com/ArmandoHasudungan
Support me:
http://www.patreon.com/armando
Instagram:
http://instagram.com/armandohasudungan
Twitter:
https://twi...
https://www.facebook.com/ArmandoHasudungan
Support me:
http://www.patreon.com/armando
Instagram:
http://instagram.com/armandohasudungan
Twitter:
https://twitter.com/Armando71021105
https://wn.com/Cancer_Metastasis
https://www.facebook.com/ArmandoHasudungan
Support me:
http://www.patreon.com/armando
Instagram:
http://instagram.com/armandohasudungan
Twitter:
https://twitter.com/Armando71021105
- published: 02 Dec 2013
- views: 294980